HOLD Gained 38.42% since buy; Raised stop to 53.95 from break even; Stock appears to be setting up or rolling over into stage 3 ; Break out price 74.83; placed alert at 74.74 to consider adding to position. Sold 1/2 on
Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company's test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company's gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.
(Info taken from TD Ameritrade) Consensus estimate $5.14 Privious Year .19 Consensus estimate is higher 2,605.26%
than previous year actual
News came out after entry:
news: Fulgent Genetics Extends Partnership with New York City Test and Trace for COVID-19 Testing, Awarded Contract for 2021 School Year
8:00 am ET December 29, 2020 (Globe Newswire) Print
Fulgent Genetics (Nasdaq: FLGT), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that the Company has extended its partnership with the New York City Department of Education (or "NYC DOE") and NYC Health + Hospitals for COVID-19 testing through the remainder of the 2021 school year. The contract was awarded after a competitive process where Fulgent demonstrated its COVID-19 testing capabilities, including its accurate and reliable test offerings, easy to use reporting systems and fast turnaround times.
Through the agreement, Fulgent will provide COVID-19 testing for thousands of students and employees at many K-12 schools in New York City on a daily basis. The NYC DOE will leverage Fulgent's FDA EUA-approved RT-PCR test, a type of test believed to provide the highest level of sensitivity and specificity for COVID-19 testing. Results will be available to individuals generally within 24 hours from the time when Fulgent receives and accepts a specimen to one of its labs.
This is not investment advice. As always, make your own decisions. I post these for the educational purposes of myself and others.
Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company's test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company's gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.
(Info taken from TD Ameritrade) Consensus estimate $5.14 Privious Year .19 Consensus estimate is higher 2,605.26%
than previous year actual
News came out after entry:
news: Fulgent Genetics Extends Partnership with New York City Test and Trace for COVID-19 Testing, Awarded Contract for 2021 School Year
8:00 am ET December 29, 2020 (Globe Newswire) Print
Fulgent Genetics (Nasdaq: FLGT), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that the Company has extended its partnership with the New York City Department of Education (or "NYC DOE") and NYC Health + Hospitals for COVID-19 testing through the remainder of the 2021 school year. The contract was awarded after a competitive process where Fulgent demonstrated its COVID-19 testing capabilities, including its accurate and reliable test offerings, easy to use reporting systems and fast turnaround times.
Through the agreement, Fulgent will provide COVID-19 testing for thousands of students and employees at many K-12 schools in New York City on a daily basis. The NYC DOE will leverage Fulgent's FDA EUA-approved RT-PCR test, a type of test believed to provide the highest level of sensitivity and specificity for COVID-19 testing. Results will be available to individuals generally within 24 hours from the time when Fulgent receives and accepts a specimen to one of its labs.
This is not investment advice. As always, make your own decisions. I post these for the educational purposes of myself and others.
Comment:
I am watching this one closely. Don't like the big red candle on big volume. It is also breaking the 10 EMA which is not a good sign. I am setting alarm at 61.00 to evaluate if this is a sell at that point. I will not hold this to the 50 day since my entry was above the 50 day. I have room to let it fall to the 21 day since I took profits earlier.
Comment:
Holding
In the midst of a global pandemic, it comes as no surprise that the healthcare sector experienced significant growth. Medical device maker and genetics company Fulgent Genetics Inc (NASDAQ: FLGT) was no exception, with the company’s stock rising from about $13 to $66 over the last 12 months.